CAJ | 학술논문

分析22例静脉溶栓治疗的急性缺血性脑卒中患者的临床资料,评价静脉溶栓治疗开展情况.静脉溶栓院内延迟平均为107 min,最主要的原因为等待相关化验结果回报.仅6例采用指南推荐的标准剂量(0.9 mg/kg)重组组织型纤溶酶原激活剂.治疗后,22例患者中有1例出现无症状性颅内出血,无症状性颅内出血发生.静脉溶栓治疗急性缺血性脑卒中有较好的安全性,应该规范化推广.
분석22례정맥용전치료적급성결혈성뇌졸중환자적림상자료,평개정맥용전치료개전정황.정맥용전원내연지평균위107 min,최주요적원인위등대상관화험결과회보.부6례채용지남추천적표준제량(0.9 mg/kg)중조조직형섬용매원격활제.치료후,22례환자중유1례출현무증상성로내출혈,무증상성로내출혈발생.정맥용전치료급성결혈성뇌졸중유교호적안전성,응해규범화추엄.
We reviewed medical data of 22 patients receiving intravenous thrombolysis therapy for acute isehemic stroke and evaluated our efforts of promoting intravenous thrombolysis for acute ischemic stroke.The mean in-hospital delay was 107 minutes.The most common reason was waiting for the results of laboratory tests.Only 6 cases received a standard dose of recombinant tissue plasminogen activator (rtPA) at 0.9 mg/kg.Only one patient had asymptomatic intracranial hemorrhage.No symptomatic hemorrhage occurred.Intravenous thrombolysis for ischemic stroke had excellent safety profile.Intravenous thrombolysis for ischemic stroke should be promoted under the guidance of standardized protocol according to the national guideline.